Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229929 | 0.92 | KDM1A (0.38) | KDM1AKDM1BKCNH2CHRNB2CHRNB4 | |
| SCHEMBL25593106 | 0.85 | KDM1A (0.33) | KDM1AKDM1BKCNH2 | |
| SCHEMBL20263723 | 0.84 | NPC1 (0.32) | — | |
| SCHEMBL26122002 | 0.81 | HTR2C (0.37) | KDM1A | |
| SCHEMBL21408540 | 0.78 | KDM1A (0.43) | KDM1AKDM1BKCNH2 | |
| SCHEMBL6616813 | 0.76 | ALDH1A1 (0.39) | — | |
| SCHEMBL1875659 | 0.76 | KDM1A (0.35) | KDM1AKDM1BKCNH2CHRNB2CHRNB4 | |
| SCHEMBL30228097 | 0.76 | KDM1A (0.35) | KDM1AKDM1BKCNH2CHRNB2CHRNB4 | |
| SCHEMBL31725635 | 0.76 | KDM1A (0.34) | KDM1AKDM1BKCNH2CHRNB2CHRNB4 | |
| SCHEMBL12656462 | 0.76 | KDM1A (0.34) | KDM1AKDM1BKCNH2CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-3782995-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019201291-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | 中国科学院上海药物研究所 | 2019-10-24 | — | — | WO | disclosed |
| EP-2488530-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202837-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-08-09 | — | — | US | disclosed |
| WO-2011057382-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202837-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | REN, AGTR1, AGTR2 | KDM1A 3890/4885KDM1B 3898/4885KCNH2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.